<DOC>
	<DOCNO>NCT02286011</DOCNO>
	<brief_summary>The purpose study evaluate safety Intramuscular Infusion Autologous Bone Marrow Stem Cells Patients With Amyotrophic Lateral Sclerosis prospective , single-center , randomize , parallel , double-blind , placebo-controlled phase I clinical trial .</brief_summary>
	<brief_title>Intramuscular Infusion Autologous Bone Marrow Stem Cells Patients With Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Diagnosis definite probable ALS accord criterion establish World Federation Neurology Patient provide reasonable assurance adherence protocol . Neurophysiological data confirm affectation low motor neuron lumbar region . Assessment motor deficit dorsiflexion foot ( 4 5 point MRC scale ) The patient must fulfill inclusion criterion . Diabetes Mellitus . Other disease may present polyneuropathy . Previous history stroke . Prior Pathology peripheral nervous system affect one low limb without clinically evident neurological sequela . Pregnant breastfeeding patient active . Patients physiologically capable become pregnant , unless use reliable contraception . Patients cardiac disease , renal , hepatic , systemic , immune may influence patient survival test . Positive serology hepatitis B , hepatitis C HIV . Clinical anesthesiologic Criteria , contraindicate either sedation extraction MO ( Altered coagulation system anticoagulated patient inability withdraw anticoagulation , hemodynamic instability , alter skin puncture site , etc . ) Included clinical trial last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>